|
|
|
| home > ebr > Winter 2009 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Independent consultant Emile Bellott looks at the changing biotech
landscape in light of the global financial crisis and considers the
likely implications for the global pharmaceutical/biotech industry |
|
|
| Mark B Hassenplug and Kai Gindner at Ernst & Young examine ways in which
pharmaceutical companies can maintain standards in supply chain management |
|
|
|
| Pharma and biotech companies often manage scientific assets and equipment on their own. Bob Moore at GE
Healthcare discusses why and how outsourcing scientific asset services can help to improve effectiveness in the lab |
|
|
| Catherine D’Arcy at PA Consulting Group describes the requirement for greater
efficiency and effectiveness in R&D operations and how working closely with
a global pharmaceutical company has prompted a review of key functions |
|
|
| Richard Barratt at Barratt Legal examines the proliferation of outsourcing
operational practices in the industry, and tells us how to get the best out of it |
|
|
|
| Mats Hellström and Björn Frendéus at BioInvent International examine the developments that
are occurring in monoclonal antibody drugs, and discuss their future in the fight against cancer |
|
|
| Birgit Jehn at QIAGEN GmbH gives an overview on HLA-Typing
or pre-therapeutic testing in AIDS patients |
|
|
|
|
| David Bunton and Lee Rankin at Biopta Ltd and Alistair Corbett at Glasgow
Caledonian University discuss opioid receptors as drug targets in gastrointestinal disorders |
|
|
| Graham Lappin at Xceleron argues that microdosing can provide important information about
a drug’s behaviour before Phase I, thereby reducing the likelihood of costly failures at a later stage |
|
|
|
| Ulrich Braumann at Bruker BioSpin and Herbert Thiele at Bruker Daltonik analyse
structure verification of small molecules using integrated MS spectrometry and NMR spectroscopy |
|
|
| Josep Prous at Thomson Reuters introduces biomarkers, identifying them
as a crucial factor in the evolution of drug research and development |
|
|
| LABALisette
Oversteegen at Datamonitor discusses combination
product market trends in the respiratory drug sector |
|
|
|
| R Keith Williams at The Clinical Biotechnology Centre, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and Angela Osborne of eXmoor pharma concepts ltd discuss small-scale biomanufacturing for clinical trials, cell and gene therapies in the UK market |
|
|
| Kate Westwell and Gina Wenham at Eden Biodesign explain
how implementing the quality cycle can deliver product value |
|
|
|
| Jacques Lhomel of Biocitech tells how one of Europe’s high-profile
life science parks has boosted resources for life sciences R&D |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries
Nemera is pleased to announce that its multidose eye dropper Novelia®
has been approved for the preservative-free formulation Cosopt iMulti®
(20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >> |
|
 |
White Papers |
 |
|
High-tech Packaging for High-tech Medicine
West Pharmaceutical Services, Inc.
As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >> |
|
 |
Industry Events |
 |
ASGCT 22nd Annual Meeting
29 April - 2 May 2019, Washington Hilton, Washington, D.C
The 2019 ASGCT Annual Meeting is expected to be the largest in Society
history, eclipsing the mark set by the 2018 meeting just last year. Join more
than 3,500 researchers, clinicians, advocates, and industry leaders in
discovering the latest science and technology surrounding gene and cell
therapy.
More info >> |
|
|
